Table 1 (Abstract A3). Use of systemic glucocorticoids and rates of selected comorbidities
Total (n=2026) | JIA onset before 2000 (n=468) | JIA onset in 2000 and later (n=1558) | |
|---|---|---|---|
Glucocorticoids at first BiKeR visit | 682 (33.7%) | 225 (48.1%) | 457 (29.3%) |
Glucocorticoids at last BiKeR visit | 52 (2.6%) | 20 (4.3%) | 32 (2.1%) |
Glucocorticoids at first JuMBO visit | 208 (10.3%) | 100 (21.4%) | 108 (6.9%) |
Glucocorticoids at last JuMBO visit | 198 (9.8%) | 90 (19.2%) | 108 (6.9%) |
Hypertension, n(%) | 58 (2.9%) | 34 (7.3)% | 24 (1.5%) |
Osteoporosis, n(%) | 72 (3.6%) | 29 (6.2%) | 43 (2.8%) |
Short stature, n(%) | 95 (4.7%) | 47 (10.4%) | 48 (3.1%) |